<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1516">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05141422</url>
  </required_header>
  <id_info>
    <org_study_id>SHR2150-I-105</org_study_id>
    <nct_id>NCT05141422</nct_id>
  </id_info>
  <brief_title>A Drug-drug Interaction Study of SHR2150 on Healthy Chinese Volunteers</brief_title>
  <official_title>A Single-centre, Single-arm, Open-label and Fixed-sequence Drug-drug Interaction Study to Evaluate the Effect of Efavirenz on the Pharmacokinetics of SHR2150 in Healthy Chinese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a single-centre, open-label, fixed-sequence, self-controlled clinical trial. It&#xD;
      is planned to enroll 20 healthy adult subjects.&#xD;
&#xD;
      Subjects will take SHR2150 on Day 1 and Day 21, and take efavirenz from Day 7 to Day 26.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 15, 2021</start_date>
  <completion_date type="Anticipated">January 22, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 15, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The study is a single-centre, single-arm, open-label and fixed-sequence clinical trial.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>from Day 1 to Day 7 after the first dose and from Day 21 to Day 27 after the second dose</time_frame>
    <description>Time to maximum observed serum concentration (Tmax) for SHR2150 after Single dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>from Day 1 to Day 7 after the first dose and from Day 21 to Day 27 after the second dose</time_frame>
    <description>Maximum observed serum concentration (Cmax) for SHR2150 after Single dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>from Day 1 to Day 7 after the first dose and from Day 21 to Day 27 after the second dose</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC0-t) for SHR2150 after Single dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf</measure>
    <time_frame>from Day 1 to Day 7 after the first dose and from Day 21 to Day 27 after the second dose</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC0-inf ) for SHR2150 after Single dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T1/2</measure>
    <time_frame>from Day 1 to Day 7 after the first dose and from Day 21 to Day 27 after the second dose</time_frame>
    <description>Time to elimination half-life (T1/2) for for SHR2150 after Single dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events and the severity of adverse events</measure>
    <time_frame>from Day 1 to Day 37 after the first dose</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Human Immunodeficiency Virus Infection</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHR2150+ efavirenz</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR2150 tablet、efavirenz</intervention_name>
    <description>SHR2150 tablet single dose, Efavirenz single dose.</description>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The subject can communicate well with the researcher, understand and comply with the&#xD;
             requirements of this study, and understand and sign the informed consent;&#xD;
&#xD;
          2. Healthy subjects aged 18 ~ 45 (including the boundary value), male and female;&#xD;
&#xD;
          3. Male body weight ≥ 50 kg, female body weight ≥ 45 kg, body mass index (BMI) within the&#xD;
             range of 18 ~ 26 kg/m2 (including the boundary value) (BMI= weight (kg)/height 2&#xD;
             (m2));&#xD;
&#xD;
          4. The physical examination, vital signs, laboratory examination, 12-lead&#xD;
             electrocardiogram, abdominal B-ultrasound, and chest radiograph are normal or have no&#xD;
             clinical significance;&#xD;
&#xD;
          5. The subjects with reproduction ability must agree to take effective contraceptive&#xD;
             measures after signing the informed consent form and within 7 months (for female) or 4&#xD;
             months (for male) until the last medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Anyone who has suffered from any clinical serious disease such as the circulatory&#xD;
             system, endocrine system, nervous system, digestive system, respiratory system,&#xD;
             urogenital system, hematology, immunology, psychiatry and metabolic abnormalities, or&#xD;
             any other disease which can affect the study results;&#xD;
&#xD;
          2. Those who have undergone surgery within 3 months before the trial, or plan to perform&#xD;
             surgery during the study period;&#xD;
&#xD;
          3. Those whose 12-lead ECG is abnormal with clinically significant or ECG QT interval&#xD;
             (QTcF) ≥ 450 ms (for male) or &gt; 460 ms (for female) or &lt; 300 ms;&#xD;
&#xD;
          4. Those who donated blood or suffered heavy blood loss (≥400 mL), received blood&#xD;
             transfusions, or used blood products within 3 months before enrollment;&#xD;
&#xD;
          5. Have a history of allergies to drugs, food or other substances;&#xD;
&#xD;
          6. Those who have used soft drugs or hard drugs; or those with positive results in urine&#xD;
             drug abuse screening;&#xD;
&#xD;
          7. Those who have participated in any clinical trials and have taken study drugs within 3&#xD;
             months before the first administration;&#xD;
&#xD;
          8. Those who have taken any medicine within 1 month before the first administration&#xD;
             (including prescription medicines, non-prescription medicines, Chinese herbal&#xD;
             medicines, vitamins, calcium tablets and other food supplements), especially the drugs&#xD;
             which have any effect on CYP3A4;&#xD;
&#xD;
          9. Regular drinkers within 3 months before the test, that is, drinking more than 15 g of&#xD;
             alcohol per day (15 g alcohol = 450 mL of beer, or 50 mL of spirits, or 150 mL of&#xD;
             wine), and any alcohol-containing products cannot be stopped during the study;&#xD;
&#xD;
         10. Hepatitis B virus surface antigen is positive, or hepatitis C virus antibody is&#xD;
             positive, or treponema pallidum antibody is positive, or human immunodeficiency virus&#xD;
             antibody is positive;&#xD;
&#xD;
         11. Women with pregnancy or within lactation period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sheng Feng</last_name>
    <phone>13817253036</phone>
    <email>sheng.feng@hengrui.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ye Xu</last_name>
    <phone>18816535787</phone>
    <email>ye.xu.yx1@hengrui.com</email>
  </overall_contact_backup>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 19, 2021</study_first_submitted>
  <study_first_submitted_qc>November 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2021</study_first_posted>
  <last_update_submitted>November 19, 2021</last_update_submitted>
  <last_update_submitted_qc>November 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Efavirenz</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

